Alteogen

Alteogen P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Alteogen (196170.KQ) as of Nov 13, 2026 is 164.59. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 385.15 — a change of -57.27% (lower).

P/CF

164.59

YoY

-57.27%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Alteogen is 2025 164.59 . P/CF (Price-to-Cash-Flow Ratio) of Alteogen was 2024 385.15 . It decreases by -57.27% lower compared to the previous year.

The Alteogen P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-2,241.98 KRW
Jan 1, 2019
2,236.91 KRW
Jan 1, 2020
13,509.82 KRW
Jan 1, 2021
-2,159.51 KRW
Jan 1, 2022
-1,142.97 KRW
Jan 1, 2023
-2,630.86 KRW
Jan 1, 2024
385.15 KRW
Jan 1, 2025
164.59 KRW
The Alteogen P/CF history
YEARP/CFYoY
164.59-57.27%
385.15-114.64%
-2,630.86+130.18%
-1,142.97-47.07%
-2,159.51-115.98%
13,509.82+503.95%
2,236.91-199.77%
-2,241.98-52.30%
-4,699.91-27.34%
-6,468.00-171.68%
9,023.69-46.55%
16,883.73—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alteogen Stock analysis

What does Alteogen do? Alteogen, Inc. generates revenue through its biobetter business segment, developing protein pharmaceuticals and cancer therapies, and its bio similar business segment, focusing on bio similar and animal medicines. The company sells growth hormone, herceptin, humira, antibodies, and other products primarily to healthcare providers and pharmaceutical distributors. Its biobetter segment targets oncology and protein-based treatments, while the bio similar segment serves both human and animal health markets with cost-effective alternatives to branded drugs. The firm's product portfolio includes growth hormone, herceptin, and humira, which are key revenue drivers in the biopharmaceutical sector. Herceptin and humira are well-established anticancer drugs, while growth hormone addresses endocrine disorders. The company's bio similar segment offers affordable versions of these therapies, appealing to budget-conscious healthcare systems and veterinary markets. Sales are concentrated in the human and animal medicine sectors, leveraging its dual focus on biobetter and bio similar products. Alteogen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alteogen stock

P/CF (Price-to-Cash-Flow Ratio) of Alteogen is 164.59 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Alteogen changed from 385.15 to 164.59, representing a -57.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Alteogen since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Alteogen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Alteogen

All Key Metrics — Alteogen